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The actions of human atrial natriuretic factor on hepatic arterial
and portal vascular beds of the anaesthetized dog
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1 The vascular actions of atrial natriuretic factor (ANF) have been assessed with other vasoactive agents
on the hepatic arterial and portal vascular beds of the anaesthetized dog.
2 Intra-arterial bolus injections of ANF (0.1-SOnmol) caused graded increases in hepatic arterial blood
flow representing a vasodilatation of relatively short duration. Vasoconstriction was never observed.
3 The maximum increase in hepatic arterial blood was the same for ANF and isoprenaline (Iso) i.e.
approximately 60-70% increase over control flow.
4 On a molar basis, ANF was less potent than Iso although over the higher dose range (10-9-10-7mol)
its vasodilator activity exceeded that of the endogenous vasodilator adrenaline.
5 Intraportal bolus injections (1.0-SOnmol) of ANF did not alter portal inflow resistance since no
changes in portal inflow pressure occurred when the portal circuit was perfused at constant inflow
volume.
6 This differential action of ANF on the hepatic arterial and portal vascular beds may provide a change
in total liver blood flow in favour of the arterial component.
7 ANF, by altering hepatic haemodynamics to favour formation of trans-sinusoidal fluid exchange, may
provide a temporary expansion of the extravascular fluid reservoir to buffer any increased venous pres-
sure. However, chronically elevated plasma levels ofANF would encourage the formation of ascitic fluid.
Introduction
Mammalian atrial myocytes synthesize and release the 28
amino acid residue peptide, atrial natriuretic factor (ANF).
Raised venous pressure, leading to atrial distension, is one of
the factors which releases ANF into the systemic circulation
(Anderson et al., 1986; Gerbes et al., 1986). In addition to
promoting natriuresis and diuresis the peptide causes hypo-
tension, due principally to a fall in peripheral vascular resist-
ance (see reviews by Genest & Cantin, 1988; Gerbes et al.,
1987). However, the regional distribution of its vasodilator
activity has not been fully examined.
Elevated central venous pressure also leads to raised
hepatic venous pressure with profound consequences for
hepatic haemodynamics and trans-sinusoidal fluid exchange
(Laine et al., 1979). Enlargement of the liver with movement of
fluid across the hepatic capsule into the peritoneal space may
be a normal, although temporary compensating mechanism to
expand the extravascular fluid space. However, chronic ele-
vation of hepatic venous pressure leads to the persistent pre-
sence of excess peritoneal (ascitic) fluid. A significant fraction
of the raised hepatic venous pressure may be transmitted
through the liver to elevate portal pressure (Bennett & Rothe,
1981) causing enlargement of the spleen (Withrington et al.,
1980), together with venous congestion and oedema of the
gastrointestinal tract.
The aim of the present experiments was to characterize the
actions of ANF on the primary intra-hepatic resistance sites in
the hepatic arterial and portal vascular beds which control
total liver blood inflow and, in addition, to assess its molar
potency relative to other vasoactive agents. In this way some
conclusions could be drawn about the role of ANF in the
regulation of total liver blood flow and its distribution
between the two inflow circuits both under normal conditions
and in those clinical situations where the systemic circulating
levels of ANF deviate significantly from normal. A prelim-
inary account of some of these results has been published
(Dhume et al., 1988).
Methods
The experiments were performed on 10 dogs (mean weight
21.9 + 2.0 kg, range 10.0-29.0 kg) anaesthetized with an intra-
venous mixture of chloralose and urethane (50 and
500mgkg1' respectively) after induction with methohexitone
sodium (6mgkg- 1). The trachea was cannulated although res-
piration was spontaneous throughout the experiment. The
right femoral vein was cannulated to administer additional
anaesthetic when appropriate. The right femoral artery was
cannulated to provide hourly blood samples for analysis of
pH, Po2 and Pco2 (Blood Gas Analyser, Instrumental Labor-
atory, Model 1302); NaHCO3 was administered i.v.
(1.Ommolmin-1) when necessary, to maintain a normal
arterial pH. The left carotid artery was cannulated and con-
nected to a strain gauge transducer (Statham P23Gb), to
provide a continuous registration of phasic systemic blood
pressure from which a continuous recording of heart rate was
derived electronically. Body temperature was maintained
within normal limits, as indicated by a buccal thermometer,
by either table heaters or overhead lamps. The animals were
heparinised (500iukg-1) once perfusion had started and half
this dose was administered hourly.
The perfusion circuits and surgery required for hepatic
arterial and portal perfusion have been described in detail pre-
viously (Corder & Withrington, 1988) and in all essential
details the same procedure was adopted for the present series.
Briefly, the hepatic artery was cannulated after ligation of
major side tributaries, and perfused with arterial blood from
the cannulated left femoral artery. The hepatic periarterial
innervation remained intact. Incorporated into the arterial
perfusion circuit was a strain gauge pressure transducer
(Statham P23Gb) and a cannulating electromagnetic flow
probe (Cardiovascular Instruments) to measure perfusion
pressure and flow respectively. These signals were heavily
1 Author for corresondence.
2 Address: Department of Pharmacology, Goa Medical College,
Panaji, Goa, India.
I Address: Department of Medicine, Klinikum Grosshadern,
University of Munich, 8000 Munchen 70, West Germany.
,'-. Macmillan Press Ltd, 1990
ANF ON HEPATIC HAEMODYNAMICS 811
damped electronically to provide mean values which were
continuously monitored on a chart recorder (Devices M19). In
addition, the signals were digitised (Data Translation DT-
2801) and processed by an IBM PC-XT computer pro-
grammed to calculate and store the absolute values of hepatic
arterial vascular resistance (mean pressure/mean flow) and the
changes induced by any experimental procedure. A 'T' piece
was included in the perfusion circuit so that vasoactive sub-
stances could be administered by bolus injection directly into
the hepatic arterial circuit without necessarily entering the
systemic circuit. This avoided either altering the conditions of
the perfusion (i.e. constant pressure) or eliciting reflex changes
in hepatic sympathetic tone.
In the portal perfusion experiments the hepatic portal vein
was cleared of all attachments and principal side branches
ligated. The spleen was removed and a wide bore polythene
tube passed retrogradely down the splenic vein to the portal
vein. The portal vein was then tied cranially just beyond the
entrance of the superior mesenteric and splenic veins so that
the venous drainage from the gastrointestinal tract was divert-
ed along the splenic vein cannula to a reservoir. The hepatic
end of the portal vein was then cannulated and blood from
the mesenteric drainage reservoir pumped, by means of a
roller pump (Watson-Marlow MHRE 1000), into the intra-
hepatic portal vascular bed. The pump was set to deliver the
same volume flow as the mesenteric venous drainage and,
once set, remained constant throughout any experiment.
Incorporated into the portal perfusion circuit between the
pump and liver was a low pressure strain-gauge transducer
and an electromagnetic flow probe to measure continuously
hepatic portal venous pressure (HPVP) and to check the
pump outflow (HPVF) respectively. A long, narrow bore,
polythene cannula was passed up the inferior vena cava (IVC)
from the right femoral vein to a point just below the dia-
phragm and opposite the entry of the hepatic veins. After suit-
able electronic damping this provided a continuous recording
of IVC pressure (IVCP). The signals from these pressure trans-
ducers were heavily damped electronically to provide mean
values which were continually monitored on a pen recorder.
Again the values were digitised and fed into a personal IBM
computer programmed to calculate hepatic portal mean
inflow resistance [(HPVP - IVCP)/HPVF] and also to store
the maximum changes in portal pressure and portal inflow
resistance induced by any experimental procedure. Incorpo-
rated into the portal circuit was a 'T' piece for injection of
vasoactive substances directly into the portal inflow.
The flow probes were calibrated with whole blood at the
end of each experiment. The liver was weighed at the end of
each experiment so that hepatic arterial and portal flows and
resistances could be expressed in terms of 100 g liver weight.
Drugs used and vehicles
Vasoactive substances were washed in with saline (0.9% w/v
NaCl solution) to give a total injectate of 2.0ml. ANF was
obtained from three sources (Sigma, Novabiochem,
Bissendorf) and made up in sterile saline which contained
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human serum albumin (10mgml- 1, Elstree) and polypep
(2.5mg ml'; low viscosity; Sigma). Close arterial or intrapor-
tal injection of this vehicle did not alter either hepatic arterial
or portal inflow resistance. The human serum albumin and
polypep were used to reduce non-specific binding of ANF
onto plastic surfaces. (± )-Isoprenaline hydrochloride
(Pharmax Ltd.) and (-)-noradrenaline acid tartrate
(Winthrop) were diluted immediately before injection in
normal saline and the solutions maintained in ice.
Statistics
Results are presented as mean + standard errors of the mean
(s.e.mean). Tests for significance refer to Students unpaired t
test.
Results
Control values
The mean liver weight was 502 + 33 g representing
2.39 + 0.16% of the body weight. In the 6 hepatic arterial per-
fusion experiments the initial mean hepatic arterial blood flow
was 187 + 12.8 ml min 1. The mean hepatic arterial perfusion
pressure was 151 + 7.0mmHg and the mean calculated
hepatic arterial vascular resistance was 0.81 + 0.05mmHg
ml ' min. These values agree with those previously obtained
in this laboratory.
In the four hepatic portal perfusion experiments the mean
initial systemic blood pressure, once portal perfusion had
started, was 115 + 3.3 mmHg. The mean hepatic portal blood
flow was 178 + 38 ml min'- or 36.7 + 7.4mlmin ' 100g. The
mean hepatic portal venous pressure was 8.50 + 0.74mmHg
and the mean inferior vena cava pressure 0.71 + 0.36mmHg;
giving a mean hepatic portal perfusion pressure gradient (i.e.
HPVP - IVCP) of 7.82 + 0.30mmHg. The mean calculated
hepatic portal inflow resistance was 0.23 + 0.045
mmHg ml - 'min 100 g. These values are similar to those
reported previously from this laboratory.
Hepatic arterial vascular responses to intra-arterial
injections
Isoprenaline The non-selective f-adrenoceptor agonist iso-
prenaline (Iso) was administered in all the hepatic arterial
preparations as a bolus injection over a range of doses (0.1-
50nmol) to construct, in each experiment, a complete dose-
response curve. The only vascular response observed to i.a.
Iso was an increase in hepatic arterial blood flow [HABF]
which was graded with dose and of relatively short duration
(Figure 1). This increase in blood flow reflects, at constant
hepatic arterial perfusion pressure [HAPP], a decrease in
hepatic arterial vascular resistance [HAVR] and therefore
vasodilatation. Previous studies have shown this vasodilator
response to be due to the activation of f2-adrenoceptors
within the hepatic arterial circuit since it is blocked by prop-
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Figure 1 Experimental records obtained from a single perfusion. Liver weight 523 g. Traces are from the top: hepatic arterial mean
blood flow (HABF), hepatic arterial mean perfusion pressure (HAPP). The two panels illustrate the vasodilator responses to intra-
arterial bolus injections of atrial natriuretic factor (ANF; 1.0-50 nmol) and isoprenaline (Iso; 2.0 and 5.0 nmol). The black dots
indicate the point of injection.
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Figure 2 Dose-response curves relating the hepatic arterial vasodila-
tor responses (expressed as the percentage increase in hepatic arterial
blood flow compared to the pre-injection control) to intra-arterial
bolus injections of atrial natriuretic factor (N) and isoprenaline (0).
All the data were obtained in the same perfusion experiment (liver
weight 294g) under comparable conditions of vascular tone. Mean
control hepatic arterial vascular resistance was 0.98 + 0.09
mmHg ml-' min.
ranolol (Richardson & Withrington, 1977) and the selective
f2-adrenoceptor antagonist, ICI 118,551 (Withrington, 1987).
The threshold dose was usually between 0.1 and 0.5 nmol and
the maximum vascular response achieved at either 10 or
20nmol. In the current series of perfusion experiments the
mean maximum increase in blood flow to Iso was 72 + 16%
of the control flow whilst the mean molar dose of Iso to
decrease the hepatic arterial vascular resistance by 50% of the
maximum was 0.42 + 0.13 nmol.
Atrial natriuretic factor In the 6 arterial perfusion prep-
arations ANF was administered as a bolus injection (on 54
occasions), in doses from 0.1-50 nmol to construct 8 dose-
response curves, in most cases from the threshold value to
maximum effect. The threshold dose of ANF to obtain a
hepatic arterial response was usually 0.1-0.5 nmol whilst the
maximum response was elicited at either 20 or 50 nmol. The
only hepatic arterial vascular response to i.a. ANF was an
increase in arterial blood flow, graded with dose, and of the
same time course as that observed with i.a. Iso (Figure 1).
These increases in arterial flow at constant perfusion pressure
reflect hepatic arterial vasodilatation. A vasoconstrictor
response to intra-arterial ANF was never observed. In any
individual experiment (e.g. Figure 2) the dose-response curve
relating the molar dose of ANF to the increase in hepatic
arterial blood flow always lay to the right of that for Iso; i.e. it
was less potent hepatic arterial vasodilator.
The mean maximum increase in hepatic arterial blood flow
to ANF was 61 + 11% of the control value; this is not signifi-
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Figure 3 Relationship between the intra-arterial molar dose of iso-
prenaline (0), atrial natriuretic factor (A) and adrenaline (0) and the
decrease in hepatic arterial vascular resistance (hepatic arterial
vasodilatation) expressed as a percentage of the control resistance
prior to the injection. The points represent the means and the vertical
bars the s.e. of at least 6 observations. The data for isoprenaline and
atrial natriuretic factor were from the current series whilst the adrena-
line results come from a previous series of similar preparations (see
Richardson & Withrington, 1977; Figure 2).
cantly different (P > 0.5) from the maximum vasodilator effect
to i.a. Iso. However there is a difference in the position of the
mean dose-response curve (Figure 3) relating the molar dose
of Iso or ANF to the decrease in hepatic arterial vascular
resistance. A consequence of this is that the mean molar ED50
to ANF i.e. the mean molar dose of ANF to reduce the vascu-
lar resistance to 50% of the maximum response, was
2.78 + 0.87 nmol; a value significantly greater than the ED50
for Iso (0.42 nmol) in the same experiments (P < 0.01) i.e. on a
molar basis ANF was less potent than Iso. In a previous series
of identical experiments (Richardson & Withrington, 1977) the
dose-response curve for adrenaline was constructed and this is
included in Figure 3 for comparison (see Discussion).
Hepatic portal responses to intraportal injections of atrial
natriureticfactor and noradrenaline
ANF was injected as a bolus into the portal circuit on 22
occasions in four perfusion preparations in doses ranging
from 1.0-50nmol. The results were unequivocal in that no
change in portal inflow pressure was observed on any
occasion (Figure 4). These observations clearly indicate that,
at constant inflow volume, no change in portal inflow resist-
ance was elicited with the range of doses ofANF administered
in this series. In 3 of the 4 experiments the higher intraportal
bolus doses of ANF were observed to cause systemic hypo-
tension indicating passage of the peptide through the liver
into the systemic circulation and peripheral vasodilatation
thus confirming the biological activity of the injectate. In the
same experiments noradrenaline (NA) was administered (6.0-
600nmol) intraportally to elicit graded increases in portal
pressure and portal vasoconstriction confirming the reactivity
of the preparation.
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Figure 4 Records of the hepatic portal mean perfusion pressure (HPVP) when the portal circuit was perfused with mesenteric blood
at constant flow (146 ml min -). The two panels illustrate the changes in portal pressure, and therefore in portal inflow resistance in
response to intraportal bolus injections of noradrenaline (NA, 60 and 120nmol) or atrial natriuretic factor (ANF 1.0, 5.0, 10 and
20 nmol). Liver weight 588 g.
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Discussion
The infusion of ANF (0.5 yg min 1) into normal man causes a
20% reduction in apparent liver blood flow (Biollaz et al.,
1986) as assessed by iodocyanin green clearance technique.
However, such a fall in flow may arise from the reflex adjust-
ments of the hepatic circulation to maintain systemic blood
pressure. In addition such information does not provide data
on any differential flow changes in the two hepatic inflow cir-
cuits. We have been concerned to establish any selective
actions of ANF on those parameters of the hepatic circulation
which control total liver blood flow and its distribution
between the arterial and portal inflow circuits.
Histochemical studies have indicated the presence of ANF
binding sites along the hepatic arterial and portal vascular ter-
ritories. Using [1125]-ANF, Bianchi et al. (1985), demonstrated
labelling in the endothelium and smooth muscle of both
arterial and portal inflow circuits of the rat. No binding sites
were observed along the mesenteric artery.
Close-arterial injection of ANF avoids any of the reflex
changes in the peripheral circulation which inevitably follow
systemic administration with consequent falls in mean BP. It
also mimics the normal route of access of ANF into the liver
via the arterial supply. In the current experiments, ANF
caused a marked hepatic arterial vasodilatation of short dura-
tion with a maximum percentage increase in blood flow not
significantly different from that elicted by the non-selective fi-
adrenoceptor agonist, Iso. However, the molar potency of
ANF, as assessed by the molar ED50, was significantly less
than Iso.
However, Iso is not a natural endogenous agent so that a
more meaningful comparison, to assess any physiological role
of ANF, is with the mixed a- and f-adrenoceptor agonist
adrenaline (Ad). The hepatic arterial responses to i.a. ADR are
complex (Figure 3) since they represent the overlapping exci-
tation of both ac- and fi2-adrenoceptors (Richardson &
Withrington, 1977) with opposing vascular effects of vasocon-
striction and vasodilatation respectively. At the lower bolus
dose range (less than 10-9mol) then ANF and Ad are equipo-
tent as hepatic arterial vasodilators. As the bolus dose is
increased the dilator activity of Ad declines presumably
because its a-agonist vasoconstrictor properties become
dominant. Therefore at doses above 10-9mol, ANF is the
more potent hepatic vasodilator. Since different systemic situ-
ations provoke the release of ANF and Ad, this different
pattern of responses of the hepatic arterial vasculature may be
appropriate. Clearly a next step in the evaluation of any
potential vascular role of ANF is to examine the hepatic
vascular interactions between ANF and other systemic vaso-
active agents.
The effect of ANF on portal haemodynamics is more diffi-
cult to assess. In the present experiments ANF caused no
change in portal inflow resistance when the bed was perfused
with mesenteric venous blood at constant flow. In this series
no experimental information was obtained about ANF on the
other principal determinant of portal haemodynamics, mesen-
teric flow. Employing chronically implanted pulsed Doppler
flow probes in the conscious normotensive rat, Gardiner et al.
(1988) observed a fall in mesenteric flow and vasoconstriction
following bolus i.v. ANF. Garcia et al. (1984) described the
relative insensitivity of isolated mesenteric resistance vessels to
the relaxant properties of ANF compared to preparations
from other vascular territories. Tentative conclusions from
these results might explain the fall in total hepatic flow re-
ported in man by Biollaz et al. (1986) since the change in total
flow would depend upon the respective extents of arterial dila-
tation and the fall in portal inflow from the mesenteric circuit.
ANF appears to have a unique spectrum of pharmacological
activity since it causes marked hepatic arterial dilatation yet
without either mesenteric or hepatic portal vasodilatation. It
may therefore change total liver blood flow in favour of the
arterial component. This differential activity of ANF may
suggest some therapeutic potential.
It is clear, however, that in terms of its absolute molar
potency, ANF is amongst the least potent vasodilator sub-
stances present in the hepatic inflow circuits. Many other
vasoactive substances, particularly peptides of gastrointestinal
origin (see review, Withrington & Richardson, 1989) enter the
liver in the portal inflow principally during digestion. It is
now established that vasoactive substances present in the
portal inflow alone may nevertheless have access to hepatic
arterial resistance sites by 'transhepatic routes' (Richardson &
Withrington, 1978; Lautt et al., 1984). It remains an important
aspect of hepatic circulatory physiology to establish any inter-
actions, on the liver vasculature, between substances of pri-
marily systemic origin (i.e. ANF) with those of GI origin (i.e.
substance P). In this way the extent to which hepatic haemo-
dynamics is related to, and integrated with, systemic and GI
events, may be evaluated.
The physiological and pathophysiological role of ANF in
liver haemodynamics remains to be fully elucidated. In the
absence of other changes then hepatic arterial vasodilatation
to ANF would increase the extent of fluid formation within
the liver by increasing mean capillary pressure, enlarge the
liver and promote movement of fluid across the liver capsule
into the peritoneal space. In this way ANF may contribute
towards buffering the effects of increased venous pressure by
temporary occupation of an enlarged extravascular space. In
the chronic condition this movement of fluid would lead to
ascites and the presence of ANF in ascitic fluid (Gerbes et al.,
1988) confirms the access of ANF to the hepatic micro-
vasculature in conditions of hepatic cirrhosis and therefore its
potential role as a factor contributing towards those hepatic
circulatory changes characteristic of cirrhosis.
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